Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Purpose We conducted a meta-analysis to evaluate clinically meaningful benefits and harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia. Methods We searched PubMed, Cochrane CENTRAL, and 5 trial registries, as well as the reference lists of identified studies. We included randomized controlled trials comparing a monoclonal antibody with placebo at a dose consistent with that used in phase 3 trials or for Food and Drug Administration approval. Studies had to report at least 1 clinically relevant benefit or harm. Data were extracted independently by at least 2 researchers for random effects meta-analysis. Changes in cognitive and functional scales were compared between groups, and each difference was assessed to determine if it met the minimal clinically important difference (MCID). Results We identified 19 publications with 23,202 total participants that evaluated 8 anti-amyloid antibodies. There were small improvements over placebo in the Alzheimer's Disease Assessment Scale (ADAS)-Cog-11 to -14 score (standardized mean difference = -0.07; 95% CI, -0.10 to -0.04), Mini Mental State Examination score (0.32 points; 95% CI, 0.13 to 0.50), and Clinical Dementia Rating-Sum of Boxes scale score (mean difference =-0.18 points; 95% CI, -0.34 to -0.03), and the combined functional scores (standardized mean difference = 0.09; 95% CI, 0.05 to 0.13). None of the changes, including those for lecanemab, aducanumab, and donanemab, exceeded the MCID. Harms included significantly increased risks of amyloid-related imaging abnormalities (ARIA)-edema (relative risk [RR] = 10.29; number needed to harm [NNH] = 9), ARIA-hemorrhage (RR = 1.74; NNH = 13), and symptomatic ARIA-edema (RR = 24.3; NNH = 86). Conclusions Although monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales in patients with Alzheimer dementia, these improvements are far below the MCID for each outcome and are accompanied by clinically meaningful harms.

What this study adds

Evidence grade: High

This is a pooled review of 23,202 participants. This meta-analysis of 19 publications with 23,202 participants found small improvements over placebo on some cognitive and functional scales with anti-amyloid antibodies, but none of the differences met the minimal clinically important difference. Reported effect size: CDR-SB mean difference -0.18 (95% CI -0.34 to -0.03), below the MCID; ARIA-oedema NNH 9.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024). Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. Annals of Family Medicine. https://doi.org/10.1370/afm.3050

Vancouver

Ebell MH, Barry HC, Baduni K, Grasso G. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. Annals of Family Medicine. 2024. doi:10.1370/afm.3050. PMID: 38253509.

BibTeX

@article{ebell2024-38253509,
  author  = {Ebell, M. H. and Barry, H. C. and Baduni, K. and Grasso, G.},
  title   = {{Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis}},
  journal = {Annals of Family Medicine},
  year    = {2024},
  doi     = {10.1370/afm.3050},
  pmid    = {38253509},
  url     = {https://doi.org/10.1370/afm.3050}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This meta-analysis of 19 publications with 23,202 participants found small improvements over placebo on some cognitive and functional scales with anti-amyloid antibodies, but none of the differences met the minimal clinically important difference. It also found significantly increased risks of amyloid-related imaging abnormalities, so the benefits appear small and come with harms.

Study details

Limitations

Pools drugs with different efficacy; MCID thresholds are debated; does not model longer-term or subgroup (e.g. low-tau) effects.

How this study scored 74/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 4 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 70 of the 94 points it could be judged on, which is 74 of 100. Total 74 of 100.70 of the 94 points we could judge = 74 of 100

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on senior author's track record and free to read, so those were left out: it earned 70 of the 94 points we could judge it on, which is 74 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Annals of Family Medicine)
Journal's citation record 2 / 4 The Annals of Family Medicine: journal h-index 161 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 4 / 4 23,202 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 4 / 7 Cited 98 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 24.5 citations a year over 4 year(s) since 2024
Impact for its field and year 3 / 6 Cited 7.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 9 other studies in this library
Still being cited 3 / 4 Cited 98 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Gabrielle Grasso holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 Michigan State University: institution h-index 1,089 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38253509)
Free to read — / 2 Access not recorded — left out of this score
Points 70 / 94 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 70 of the 94 points we could judge it on is 74 out of 100.
Total 74 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →